期刊文献+

21例度洛西汀治疗糖尿病足病疼痛临床分析 被引量:2

Study of duloxetine treatment with diabetic foot pain in 21 cases
下载PDF
导出
摘要 目的评价度洛西汀治疗糖尿病足病疼痛的有效性和安全性。方法将42例糖尿病足病疼痛患者随机分为试验组(21例)和对照组(21例),对照组予降糖、营养神经等常规治疗,试验组在常规治疗的基础上加用度洛西汀60mg,每日1次,采用视觉模拟评分法(VAS)对疼痛进行评定,观察两组患者治疗前和治疗4周后疼痛改善情况。结果两组患者治疗后疼痛均有明显减轻。试验组总有效率为100.0%,对照组总有效率为80.9%,试验组疗效优于对照组,差异有统计学意义(P〈0.05)。结论度洛西汀治疗2型糖尿病足病疼痛是一种有效的方法,且有较好的安全性和耐受性。 Objective To evaluate the efficacy and safety of Duloxetine treatment with pain in diabetic foot. Methods 42 patients with pain in diabetic foot were divided into two groups. Patients in treatment group( n = 21 ) were treated by combination of routine treatment and duloxetine 60 mg once dai- ly. Patients in control group( n = 21 ) were treated by routine treatment: insulin, trophic nerve and so on. Using visual analysis scale(VAS) to assess the level of pain and observe the improvement of pain between two groups after treatment. Results Two groups of patients showed significant improvement of pain after treatment,the pain was significantly reduced. The total effective rate was 100.0% in the treatment group and 80.9% in the control group,the effect of treatment group was significantly better than the control group( P 〈 0.05 ). Conclusion The short - term study of Duloxetine on pain in diabetic foot is an effective way, and have good safety and tolerability.
出处 《临床内科杂志》 CAS 2012年第5期335-336,共2页 Journal of Clinical Internal Medicine
关键词 度洛西汀 糖尿病足病 疼痛 Duloxetine Diabetic foot Pain
  • 相关文献

参考文献6

二级参考文献30

  • 1高静芳,陶明,张萍,唐文新.抗抑郁药物治疗的依从性观察[J].上海精神医学,2003,15(3):143-145. 被引量:23
  • 2郭玉璞.痛性糖尿病神经病诊断和治疗[J].中国糖尿病杂志,1994,2(3):168-169. 被引量:5
  • 3GartlehnerG GaynesBN HansenRA etal.比较第二代抗抑郁药物的益处与危害.精神相关疾病论坛,2009,2:20-20.
  • 4Huskisson EC. Visual analogue scale[ M ] .//Melzack R. pain measure- ment and assessment. New York: Raven press, 1999:33.
  • 5Khan GM, Chen SR, Pan IlL. Role d" primary afferent nerves in allodyni- a caused by diabetic neureputhy in rats[J]. Neuroscience, 2002,114(2) : 291.
  • 6Iyenar S, Webster AA, Hemrick-Luecke SK, et al. Efficacy of duloxe-tine, a potent and babanced, serotonin-norepine phrine inhibitor in persis-tent pain models in rats[ J ]. J Pharmacol Exp Ther, 2004,311 (2) : 576.
  • 7Wong DT. Byhaster FP. Dual serotenin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype[ J ]. Pwg Drug Res,2002,58:169.
  • 8Wemicke JF, Pritchett YL, l)souzad N,et al,A randomized controlled trial of duloxetine in diabetic peripheral nenropathic pain[ J ]. Neurology, 2006,67(8) : 1411.
  • 9Goldstein DJ, Im Y, Ddtke MJ, et al, Duloxetine vs placebo in patients with painful diabetic neuropathy[ J]. Pain,2005,116( 1 - 2) : 109.
  • 10Ziegler D,Pritchett YL, Wang F, et al. Impact of disease characteristics on the egicacy of duloxetine in diabetic peripheral neuropathic pain[ J ]. Diabetes Care,2007,30(3) :664.

共引文献20

同被引文献25

引证文献2

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部